Spero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third-Generation Anti-CD40L Antibody
Spero Therapeutics has secured exclusive global rights, excluding Greater China, to Innovent Biologics' SP001 (IBI355), a third-generation anti-CD40L antibody currently targeting immune-mediated diseases. Under the agreement, Innovent is eligible to receive approximately US$1.1 billion in total milestone payments along with tiered royalties, while Spero plans to initiate a Phase 2 trial for IgG4-related disease in Q2 2027.
Key figures
- Drug Name
- SP001 (IBI355)
- Deal Value Usd
- US$1.1 billion
- Phase Of Trial
- Phase 2
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.